Leonard M, Ryan M P, Watson A J, Schramek H, Healy E
Department of Pharmacology, University College Dublin, Ireland.
Kidney Int. 1999 Oct;56(4):1366-77. doi: 10.1046/j.1523-1755.1999.00664.x.
Both interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) are pleiotropic cytokines that have been implicated in the development of glomerular and tubular injury in various forms of immune-mediated renal disease, including glomerulonephritis. Although TNF-alpha has been shown to stimulate IL-6 production in renal cells in culture, the signaling mechanisms that regulate IL-6 production are not fully understood. The aim of this study was to examine the role of the p38 and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathways in regulating TNF-alpha-mediated IL-6 production from both primary human mesangial cells (HMCs) and human proximal tubular (HPT) cells.
Primary mesangial and proximal tubular cells were prepared from nephrectomized human kidney tissue. Cells were treated for 24 hours with TNF-alpha in the presence and absence of the specific p38 and ERK1,2 MAPK inhibitors SB203580 and PD98059, respectively, either alone or in combination. IL-6 levels in the cell culture media were measured by enzyme-linked immunosorbent assay. MAPK activation was demonstrated by immunoblot for the active kinase (tyrosine/threonine phosphorylated) in whole cell extracts using phospho-specific antibodies. p38 MAPK activity in HPT cells was measured using an in vitro immunokinase assay using ATF2 as the substrate.
TNF-alpha (0.1 to 100 ng/ml) stimulated a dose-dependent increase in IL-6 production in both renal cell types. The activation of the p38 and the ERK1,2 MAPKs occurred following TNF-alpha stimulation. The role of these activations in IL-6 production was confirmed by the ability of both inhibitors SB203580 (1 to 30 microM) and PD98059 (0.01 to 10 microM) to inhibit basal and TNF-alpha-stimulated IL-6 production in both cell types. The addition of both inhibitors in combination caused greater decreases in IL-6 production compared with either inhibitor alone. Pretreatment with SB203580 (10 microM) had no effect on basal or TNF-alpha-stimulated phosphorylation of p38 MAPK but completely abolished TNF-alpha-stimulated p38 MAPK activity. PD98059 decreased both basal and TNF-alpha-stimulated phosphorylation of ERK1,2.
This study provides evidence that both the p38 and ERK MAPK pathways are important for the regulation of the production of IL-6 from the proximal tubular and glomerular mesangial regions of the nephron. In response to TNF-alpha, the activation of both pathways leads to IL-6 production. These findings could aid in an understanding of the cellular mechanisms that regulate IL-6 production and could provide insights into possible pharmacological strategies in inflammatory renal disease.
白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)都是多效性细胞因子,在包括肾小球肾炎在内的各种免疫介导性肾脏疾病的肾小球和肾小管损伤发展过程中发挥作用。尽管已证明TNF-α可在培养的肾细胞中刺激IL-6的产生,但调节IL-6产生的信号传导机制尚未完全明确。本研究的目的是探讨p38和细胞外信号调节激酶(ERK)丝裂原活化蛋白激酶(MAPK)途径在调节原发性人系膜细胞(HMC)和人近端肾小管(HPT)细胞中TNF-α介导的IL-6产生中的作用。
从切除的人肾组织中制备原发性系膜细胞和近端肾小管细胞。分别单独或联合使用特异性p38和ERK1、2 MAPK抑制剂SB203580和PD98059,在存在和不存在TNF-α的情况下,将细胞处理24小时。通过酶联免疫吸附测定法测量细胞培养基中的IL-6水平。使用磷酸特异性抗体通过免疫印迹法检测全细胞提取物中活性激酶(酪氨酸/苏氨酸磷酸化)来证明MAPK的激活。使用以ATF2为底物的体外免疫激酶测定法测量HPT细胞中的p38 MAPK活性。
TNF-α(0.1至100 ng/ml)刺激两种肾细胞类型中IL-6产生呈剂量依赖性增加。TNF-α刺激后,p38和ERK1、2 MAPK被激活。抑制剂SB203580(1至30 microM)和PD98059(0.01至10 microM)均能抑制两种细胞类型中基础和TNF-α刺激的IL-6产生,从而证实了这些激活在IL-6产生中的作用。与单独使用任何一种抑制剂相比,联合使用两种抑制剂导致IL-6产生的降低幅度更大。用SB203580(10 microM)预处理对基础或TNF-α刺激的p38 MAPK磷酸化没有影响,但完全消除了TNF-α刺激下的p38 MAPK活性。PD98059降低了基础和TNF-α刺激下ERK1、2的磷酸化。
本研究提供的证据表明,p38和ERK MAPK途径对于调节肾单位近端肾小管和肾小球系膜区域IL-6的产生都很重要。响应TNF-α时,这两种途径的激活都会导致IL-6的产生。这些发现有助于理解调节IL-6产生的细胞机制,并可为炎症性肾脏疾病的可能药理策略提供见解。